Psoriasis Drug Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type
By: HDIN Research
Published: 2025-05-25
Pages: 99
Market Research Report Price
- Single User License (1 Users) $ 3,200
- Team License (2~5 Users) $ 4,200
- Corporate License (>5 Users) $ 5,200
Psoriasis Drugs Market Summary
Introduction and Market Overview
Psoriasis drugs encompass a range of treatments, including biologics, small molecules, and topical therapies, designed to manage chronic inflammatory skin conditions affecting approximately 125 million people globally, with a prevalence of 2-3%. The market is propelled by the high burden of psoriasis, particularly in high-income countries where prevalence reaches 5-8%, and the significant impact of psoriatic arthritis, affecting 20-30% of patients. Advances in biologics, such as IL-17 and IL-23 inhibitors, have revolutionized treatment, achieving up to 90% reduction in disease severity (PASI 90). The aging population, lifestyle factors like stress and obesity, and increased diagnosis rates further drive demand. The global psoriasis drugs market is estimated at USD 15-23 billion in 2025, with a compound annual growth rate (CAGR) of 8%-15% through 2030.
Regional Market Trends
North America: The U.S. leads with widespread access to biologics and robust dermatology services, while Canada focuses on expanding treatment access in rural areas.
Europe: Germany, France, and the UK drive growth with high diagnosis rates and strong reimbursement for biologics.
Asia Pacific: China and India see rising demand due to increasing awareness and urban lifestyle factors, with Japan emphasizing advanced biologics.
Rest of the World: Brazil expands public health access to generics, while the Middle East invests in dermatology infrastructure.
Distribution Channel Analysis
Hospital Pharmacies: Expected growth of 8.5%-15.5%, driven by biologic administration needs. Trends focus on infusion centers for complex therapies.
Retail Pharmacies: Projected growth of 8.2%-15.2%, linked to topical and oral treatments. Advances emphasize patient convenience.
Others: Anticipated growth of 7.8%-14.8%, covering online pharmacies. Trends highlight digital prescription platforms.
Type Analysis
Tumor Necrosis Factor Inhibitors: Expected growth of 7.8%-14.8%, valued for established efficacy. Trends focus on biosimilars reducing costs.
Interleukin Inhibitors: Projected growth of 9.0%-16.0%, favored for high PASI 90 rates. Advances emphasize IL-23 and IL-17 specificity.
Vitamin D Analogues: Anticipated growth of 7.5%-14.5%, suited for mild cases. Trends highlight combination therapies.
Corticosteroids: Expected growth of 7.3%-14.3%, used for topical relief. Developments prioritize low-potency options.
Others: Anticipated growth of 7.0%-14.0%, covering small molecules. Trends focus on oral therapies like apremilast.
Key Market Players
Amgen: Develops biologics targeting inflammatory pathways.
Johnson & Johnson: Offers IL-12/23 inhibitors for systemic treatment.
Novartis: Specializes in IL-17 inhibitors for severe psoriasis.
AbbVie: Provides IL-23 inhibitors with high efficacy.
Eli Lilly: Focuses on advanced biologics for psoriatic arthritis.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to high R&D costs and regulatory barriers, but biosimilars lower entry hurdles.
Threat of Substitutes: Low, as alternative therapies like phototherapy lack biologics’ efficacy, though lifestyle changes compete.
Bargaining Power of Buyers: Moderate, with patients seeking affordable options, but specialized biologics limit choices.
Bargaining Power of Suppliers: Low, with multiple providers of active pharmaceutical ingredients.
Competitive Rivalry: High, with players competing on efficacy, safety, and pricing.
Market Opportunities and Challenges
Opportunities:
Addressing psoriasis, affecting 125 million people, with advanced biologics.
Leveraging high diagnosis rates, up to 80% in high-income countries.
Managing psoriatic arthritis, impacting 20-30% of patients, with IL inhibitors.
Utilizing reimbursement policies, with 70% biologic coverage in the EU.
Meeting demand driven by lifestyle factors like stress and obesity.
Supporting an aging population with metabolic syndrome-related psoriasis.
Challenges:
High costs of biologics, limiting access in low-income regions.
Regulatory delays, with approvals taking 1-2 years.
Patient adherence issues with long-term therapies.
Competition from biosimilars reducing prices.
Side effects of biologics requiring monitoring.
Introduction and Market Overview
Psoriasis drugs encompass a range of treatments, including biologics, small molecules, and topical therapies, designed to manage chronic inflammatory skin conditions affecting approximately 125 million people globally, with a prevalence of 2-3%. The market is propelled by the high burden of psoriasis, particularly in high-income countries where prevalence reaches 5-8%, and the significant impact of psoriatic arthritis, affecting 20-30% of patients. Advances in biologics, such as IL-17 and IL-23 inhibitors, have revolutionized treatment, achieving up to 90% reduction in disease severity (PASI 90). The aging population, lifestyle factors like stress and obesity, and increased diagnosis rates further drive demand. The global psoriasis drugs market is estimated at USD 15-23 billion in 2025, with a compound annual growth rate (CAGR) of 8%-15% through 2030.
Regional Market Trends
North America: The U.S. leads with widespread access to biologics and robust dermatology services, while Canada focuses on expanding treatment access in rural areas.
Europe: Germany, France, and the UK drive growth with high diagnosis rates and strong reimbursement for biologics.
Asia Pacific: China and India see rising demand due to increasing awareness and urban lifestyle factors, with Japan emphasizing advanced biologics.
Rest of the World: Brazil expands public health access to generics, while the Middle East invests in dermatology infrastructure.
Distribution Channel Analysis
Hospital Pharmacies: Expected growth of 8.5%-15.5%, driven by biologic administration needs. Trends focus on infusion centers for complex therapies.
Retail Pharmacies: Projected growth of 8.2%-15.2%, linked to topical and oral treatments. Advances emphasize patient convenience.
Others: Anticipated growth of 7.8%-14.8%, covering online pharmacies. Trends highlight digital prescription platforms.
Type Analysis
Tumor Necrosis Factor Inhibitors: Expected growth of 7.8%-14.8%, valued for established efficacy. Trends focus on biosimilars reducing costs.
Interleukin Inhibitors: Projected growth of 9.0%-16.0%, favored for high PASI 90 rates. Advances emphasize IL-23 and IL-17 specificity.
Vitamin D Analogues: Anticipated growth of 7.5%-14.5%, suited for mild cases. Trends highlight combination therapies.
Corticosteroids: Expected growth of 7.3%-14.3%, used for topical relief. Developments prioritize low-potency options.
Others: Anticipated growth of 7.0%-14.0%, covering small molecules. Trends focus on oral therapies like apremilast.
Key Market Players
Amgen: Develops biologics targeting inflammatory pathways.
Johnson & Johnson: Offers IL-12/23 inhibitors for systemic treatment.
Novartis: Specializes in IL-17 inhibitors for severe psoriasis.
AbbVie: Provides IL-23 inhibitors with high efficacy.
Eli Lilly: Focuses on advanced biologics for psoriatic arthritis.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to high R&D costs and regulatory barriers, but biosimilars lower entry hurdles.
Threat of Substitutes: Low, as alternative therapies like phototherapy lack biologics’ efficacy, though lifestyle changes compete.
Bargaining Power of Buyers: Moderate, with patients seeking affordable options, but specialized biologics limit choices.
Bargaining Power of Suppliers: Low, with multiple providers of active pharmaceutical ingredients.
Competitive Rivalry: High, with players competing on efficacy, safety, and pricing.
Market Opportunities and Challenges
Opportunities:
Addressing psoriasis, affecting 125 million people, with advanced biologics.
Leveraging high diagnosis rates, up to 80% in high-income countries.
Managing psoriatic arthritis, impacting 20-30% of patients, with IL inhibitors.
Utilizing reimbursement policies, with 70% biologic coverage in the EU.
Meeting demand driven by lifestyle factors like stress and obesity.
Supporting an aging population with metabolic syndrome-related psoriasis.
Challenges:
High costs of biologics, limiting access in low-income regions.
Regulatory delays, with approvals taking 1-2 years.
Patient adherence issues with long-term therapies.
Competition from biosimilars reducing prices.
Side effects of biologics requiring monitoring.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Psoriasis Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Psoriasis Drug Market in North America (2020-2030)
8.1 Psoriasis Drug Market Size
8.2 Psoriasis Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Psoriasis Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Psoriasis Drug Market in South America (2020-2030)
9.1 Psoriasis Drug Market Size
9.2 Psoriasis Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Psoriasis Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Psoriasis Drug Market in Asia & Pacific (2020-2030)
10.1 Psoriasis Drug Market Size
10.2 Psoriasis Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Psoriasis Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Psoriasis Drug Market in Europe (2020-2030)
11.1 Psoriasis Drug Market Size
11.2 Psoriasis Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Psoriasis Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Psoriasis Drug Market in MEA (2020-2030)
12.1 Psoriasis Drug Market Size
12.2 Psoriasis Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Psoriasis Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Psoriasis Drug Market (2020-2025)
13.1 Psoriasis Drug Market Size
13.2 Psoriasis Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Psoriasis Drug Market Size by Type
Chapter 14 Global Psoriasis Drug Market Forecast (2025-2030)
14.1 Psoriasis Drug Market Size Forecast
14.2 Psoriasis Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Psoriasis Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Amgen
15.1.1 Company Profile
15.1.2 Main Business and Psoriasis Drug Information
15.1.3 SWOT Analysis of Amgen
15.1.4 Amgen Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Johnson & Johnson
15.2.1 Company Profile
15.2.2 Main Business and Psoriasis Drug Information
15.2.3 SWOT Analysis of Johnson & Johnson
15.2.4 Johnson & Johnson Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Novartis
15.3.1 Company Profile
15.3.2 Main Business and Psoriasis Drug Information
15.3.3 SWOT Analysis of Novartis
15.3.4 Novartis Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 AbbVie
15.4.1 Company Profile
15.4.2 Main Business and Psoriasis Drug Information
15.4.3 SWOT Analysis of AbbVie
15.4.4 AbbVie Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 Eli Lilly
15.5.1 Company Profile
15.5.2 Main Business and Psoriasis Drug Information
15.5.3 SWOT Analysis of Eli Lilly
15.5.4 Eli Lilly Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 AstraZeneca
15.6.1 Company Profile
15.6.2 Main Business and Psoriasis Drug Information
15.6.3 SWOT Analysis of AstraZeneca
15.6.4 AstraZeneca Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 UCB S.A.
15.7.1 Company Profile
15.7.2 Main Business and Psoriasis Drug Information
15.7.3 SWOT Analysis of UCB S.A.
15.7.4 UCB S.A. Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 Merck
15.8.1 Company Profile
15.8.2 Main Business and Psoriasis Drug Information
15.8.3 SWOT Analysis of Merck
15.8.4 Merck Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Psoriasis Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Psoriasis Drug Market in North America (2020-2030)
8.1 Psoriasis Drug Market Size
8.2 Psoriasis Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Psoriasis Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Psoriasis Drug Market in South America (2020-2030)
9.1 Psoriasis Drug Market Size
9.2 Psoriasis Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Psoriasis Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Psoriasis Drug Market in Asia & Pacific (2020-2030)
10.1 Psoriasis Drug Market Size
10.2 Psoriasis Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Psoriasis Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Psoriasis Drug Market in Europe (2020-2030)
11.1 Psoriasis Drug Market Size
11.2 Psoriasis Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Psoriasis Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Psoriasis Drug Market in MEA (2020-2030)
12.1 Psoriasis Drug Market Size
12.2 Psoriasis Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Psoriasis Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Psoriasis Drug Market (2020-2025)
13.1 Psoriasis Drug Market Size
13.2 Psoriasis Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Psoriasis Drug Market Size by Type
Chapter 14 Global Psoriasis Drug Market Forecast (2025-2030)
14.1 Psoriasis Drug Market Size Forecast
14.2 Psoriasis Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Psoriasis Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Amgen
15.1.1 Company Profile
15.1.2 Main Business and Psoriasis Drug Information
15.1.3 SWOT Analysis of Amgen
15.1.4 Amgen Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Johnson & Johnson
15.2.1 Company Profile
15.2.2 Main Business and Psoriasis Drug Information
15.2.3 SWOT Analysis of Johnson & Johnson
15.2.4 Johnson & Johnson Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Novartis
15.3.1 Company Profile
15.3.2 Main Business and Psoriasis Drug Information
15.3.3 SWOT Analysis of Novartis
15.3.4 Novartis Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 AbbVie
15.4.1 Company Profile
15.4.2 Main Business and Psoriasis Drug Information
15.4.3 SWOT Analysis of AbbVie
15.4.4 AbbVie Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 Eli Lilly
15.5.1 Company Profile
15.5.2 Main Business and Psoriasis Drug Information
15.5.3 SWOT Analysis of Eli Lilly
15.5.4 Eli Lilly Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 AstraZeneca
15.6.1 Company Profile
15.6.2 Main Business and Psoriasis Drug Information
15.6.3 SWOT Analysis of AstraZeneca
15.6.4 AstraZeneca Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 UCB S.A.
15.7.1 Company Profile
15.7.2 Main Business and Psoriasis Drug Information
15.7.3 SWOT Analysis of UCB S.A.
15.7.4 UCB S.A. Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 Merck
15.8.1 Company Profile
15.8.2 Main Business and Psoriasis Drug Information
15.8.3 SWOT Analysis of Merck
15.8.4 Merck Psoriasis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Table Abbreviation And Acronyms
Table Research Scope Of Psoriasis Drug Report
Table Data Sources Of Psoriasis Drug Report
Table Major Assumptions Of Psoriasis Drug Report
Table Psoriasis Drug Classification
Table Psoriasis Drug Applications
Table Drivers Of Psoriasis Drug Market
Table Restraints Of Psoriasis Drug Market
Table Opportunities Of Psoriasis Drug Market
Table Threats Of Psoriasis Drug Market
Table Raw Materials Suppliers
Table Different Production Methods Of Psoriasis Drug
Table Cost Structure Analysis Of Psoriasis Drug
Table Key End Users
Table Latest News Of Psoriasis Drug Market
Table Merger And Acquisition
Table Planned/Future Project Of Psoriasis Drug Market
Table Policy Of Psoriasis Drug Market
Table 2020-2030 North America Psoriasis Drug Market Size
Table 2020-2030 North America Psoriasis Drug Market Size By Application
Table 2020-2025 North America Psoriasis Drug Key Players Revenue
Table 2020-2025 North America Psoriasis Drug Key Players Market Share
Table 2020-2030 North America Psoriasis Drug Market Size By Type
Table 2020-2030 United States Psoriasis Drug Market Size
Table 2020-2030 Canada Psoriasis Drug Market Size
Table 2020-2030 Mexico Psoriasis Drug Market Size
Table 2020-2030 South America Psoriasis Drug Market Size
Table 2020-2030 South America Psoriasis Drug Market Size By Application
Table 2020-2025 South America Psoriasis Drug Key Players Revenue
Table 2020-2025 South America Psoriasis Drug Key Players Market Share
Table 2020-2030 South America Psoriasis Drug Market Size By Type
Table 2020-2030 Brazil Psoriasis Drug Market Size
Table 2020-2030 Argentina Psoriasis Drug Market Size
Table 2020-2030 Chile Psoriasis Drug Market Size
Table 2020-2030 Peru Psoriasis Drug Market Size
Table 2020-2030 Asia & Pacific Psoriasis Drug Market Size
Table 2020-2030 Asia & Pacific Psoriasis Drug Market Size By Application
Table 2020-2025 Asia & Pacific Psoriasis Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Psoriasis Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Psoriasis Drug Market Size By Type
Table 2020-2030 China Psoriasis Drug Market Size
Table 2020-2030 India Psoriasis Drug Market Size
Table 2020-2030 Japan Psoriasis Drug Market Size
Table 2020-2030 South Korea Psoriasis Drug Market Size
Table 2020-2030 Southeast Asia Psoriasis Drug Market Size
Table 2020-2030 Australia Psoriasis Drug Market Size
Table 2020-2030 Europe Psoriasis Drug Market Size
Table 2020-2030 Europe Psoriasis Drug Market Size By Application
Table 2020-2025 Europe Psoriasis Drug Key Players Revenue
Table 2020-2025 Europe Psoriasis Drug Key Players Market Share
Table 2020-2030 Europe Psoriasis Drug Market Size By Type
Table 2020-2030 Germany Psoriasis Drug Market Size
Table 2020-2030 France Psoriasis Drug Market Size
Table 2020-2030 United Kingdom Psoriasis Drug Market Size
Table 2020-2030 Italy Psoriasis Drug Market Size
Table 2020-2030 Spain Psoriasis Drug Market Size
Table 2020-2030 Belgium Psoriasis Drug Market Size
Table 2020-2030 Netherlands Psoriasis Drug Market Size
Table 2020-2030 Austria Psoriasis Drug Market Size
Table 2020-2030 Poland Psoriasis Drug Market Size
Table 2020-2030 Russia Psoriasis Drug Market Size
Table 2020-2030 Mea Psoriasis Drug Market Size
Table 2020-2030 Mea Psoriasis Drug Market Size By Application
Table 2020-2025 Mea Psoriasis Drug Key Players Revenue
Table 2020-2025 Mea Psoriasis Drug Key Players Market Share
Table 2020-2030 Mea Psoriasis Drug Market Size By Type
Table 2020-2030 Egypt Psoriasis Drug Market Size
Table 2020-2030 Israel Psoriasis Drug Market Size
Table 2020-2030 South Africa Psoriasis Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Psoriasis Drug Market Size
Table 2020-2030 Turkey Psoriasis Drug Market Size
Table 2020-2025 Global Psoriasis Drug Market Size By Region
Table 2020-2025 Global Psoriasis Drug Market Size Share By Region
Table 2020-2025 Global Psoriasis Drug Market Size By Application
Table 2020-2025 Global Psoriasis Drug Market Share By Application
Table 2020-2025 Global Psoriasis Drug Key Vendors Revenue
Table 2020-2025 Global Psoriasis Drug Key Vendors Market Share
Table 2020-2025 Global Psoriasis Drug Market Size By Type
Table 2020-2025 Global Psoriasis Drug Market Share By Type
Table 2025-2030 Global Psoriasis Drug Market Size By Region
Table 2025-2030 Global Psoriasis Drug Market Size Share By Region
Table 2025-2030 Global Psoriasis Drug Market Size By Application
Table 2025-2030 Global Psoriasis Drug Market Share By Application
Table 2025-2030 Global Psoriasis Drug Key Vendors Revenue
Table 2025-2030 Global Psoriasis Drug Key Vendors Market Share
Table 2025-2030 Global Psoriasis Drug Market Size By Type
Table 2025-2030 Psoriasis Drug Global Market Share By Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Psoriasis Drug Picture
Figure 2020-2030 North America Psoriasis Drug Market Size And Cagr
Figure 2020-2030 South America Psoriasis Drug Market Size And Cagr
Figure 2020-2030 Asia & Pacific Psoriasis Drug Market Size And Cagr
Figure 2020-2030 Europe Psoriasis Drug Market Size And Cagr
Figure 2020-2030 Mea Psoriasis Drug Market Size And Cagr
Figure 2020-2025 Global Psoriasis Drug Market Size And Growth Rate
Figure 2025-2030 Global Psoriasis Drug Market Size And Growth Rate
Table Research Scope Of Psoriasis Drug Report
Table Data Sources Of Psoriasis Drug Report
Table Major Assumptions Of Psoriasis Drug Report
Table Psoriasis Drug Classification
Table Psoriasis Drug Applications
Table Drivers Of Psoriasis Drug Market
Table Restraints Of Psoriasis Drug Market
Table Opportunities Of Psoriasis Drug Market
Table Threats Of Psoriasis Drug Market
Table Raw Materials Suppliers
Table Different Production Methods Of Psoriasis Drug
Table Cost Structure Analysis Of Psoriasis Drug
Table Key End Users
Table Latest News Of Psoriasis Drug Market
Table Merger And Acquisition
Table Planned/Future Project Of Psoriasis Drug Market
Table Policy Of Psoriasis Drug Market
Table 2020-2030 North America Psoriasis Drug Market Size
Table 2020-2030 North America Psoriasis Drug Market Size By Application
Table 2020-2025 North America Psoriasis Drug Key Players Revenue
Table 2020-2025 North America Psoriasis Drug Key Players Market Share
Table 2020-2030 North America Psoriasis Drug Market Size By Type
Table 2020-2030 United States Psoriasis Drug Market Size
Table 2020-2030 Canada Psoriasis Drug Market Size
Table 2020-2030 Mexico Psoriasis Drug Market Size
Table 2020-2030 South America Psoriasis Drug Market Size
Table 2020-2030 South America Psoriasis Drug Market Size By Application
Table 2020-2025 South America Psoriasis Drug Key Players Revenue
Table 2020-2025 South America Psoriasis Drug Key Players Market Share
Table 2020-2030 South America Psoriasis Drug Market Size By Type
Table 2020-2030 Brazil Psoriasis Drug Market Size
Table 2020-2030 Argentina Psoriasis Drug Market Size
Table 2020-2030 Chile Psoriasis Drug Market Size
Table 2020-2030 Peru Psoriasis Drug Market Size
Table 2020-2030 Asia & Pacific Psoriasis Drug Market Size
Table 2020-2030 Asia & Pacific Psoriasis Drug Market Size By Application
Table 2020-2025 Asia & Pacific Psoriasis Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Psoriasis Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Psoriasis Drug Market Size By Type
Table 2020-2030 China Psoriasis Drug Market Size
Table 2020-2030 India Psoriasis Drug Market Size
Table 2020-2030 Japan Psoriasis Drug Market Size
Table 2020-2030 South Korea Psoriasis Drug Market Size
Table 2020-2030 Southeast Asia Psoriasis Drug Market Size
Table 2020-2030 Australia Psoriasis Drug Market Size
Table 2020-2030 Europe Psoriasis Drug Market Size
Table 2020-2030 Europe Psoriasis Drug Market Size By Application
Table 2020-2025 Europe Psoriasis Drug Key Players Revenue
Table 2020-2025 Europe Psoriasis Drug Key Players Market Share
Table 2020-2030 Europe Psoriasis Drug Market Size By Type
Table 2020-2030 Germany Psoriasis Drug Market Size
Table 2020-2030 France Psoriasis Drug Market Size
Table 2020-2030 United Kingdom Psoriasis Drug Market Size
Table 2020-2030 Italy Psoriasis Drug Market Size
Table 2020-2030 Spain Psoriasis Drug Market Size
Table 2020-2030 Belgium Psoriasis Drug Market Size
Table 2020-2030 Netherlands Psoriasis Drug Market Size
Table 2020-2030 Austria Psoriasis Drug Market Size
Table 2020-2030 Poland Psoriasis Drug Market Size
Table 2020-2030 Russia Psoriasis Drug Market Size
Table 2020-2030 Mea Psoriasis Drug Market Size
Table 2020-2030 Mea Psoriasis Drug Market Size By Application
Table 2020-2025 Mea Psoriasis Drug Key Players Revenue
Table 2020-2025 Mea Psoriasis Drug Key Players Market Share
Table 2020-2030 Mea Psoriasis Drug Market Size By Type
Table 2020-2030 Egypt Psoriasis Drug Market Size
Table 2020-2030 Israel Psoriasis Drug Market Size
Table 2020-2030 South Africa Psoriasis Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Psoriasis Drug Market Size
Table 2020-2030 Turkey Psoriasis Drug Market Size
Table 2020-2025 Global Psoriasis Drug Market Size By Region
Table 2020-2025 Global Psoriasis Drug Market Size Share By Region
Table 2020-2025 Global Psoriasis Drug Market Size By Application
Table 2020-2025 Global Psoriasis Drug Market Share By Application
Table 2020-2025 Global Psoriasis Drug Key Vendors Revenue
Table 2020-2025 Global Psoriasis Drug Key Vendors Market Share
Table 2020-2025 Global Psoriasis Drug Market Size By Type
Table 2020-2025 Global Psoriasis Drug Market Share By Type
Table 2025-2030 Global Psoriasis Drug Market Size By Region
Table 2025-2030 Global Psoriasis Drug Market Size Share By Region
Table 2025-2030 Global Psoriasis Drug Market Size By Application
Table 2025-2030 Global Psoriasis Drug Market Share By Application
Table 2025-2030 Global Psoriasis Drug Key Vendors Revenue
Table 2025-2030 Global Psoriasis Drug Key Vendors Market Share
Table 2025-2030 Global Psoriasis Drug Market Size By Type
Table 2025-2030 Psoriasis Drug Global Market Share By Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Psoriasis Drug Picture
Figure 2020-2030 North America Psoriasis Drug Market Size And Cagr
Figure 2020-2030 South America Psoriasis Drug Market Size And Cagr
Figure 2020-2030 Asia & Pacific Psoriasis Drug Market Size And Cagr
Figure 2020-2030 Europe Psoriasis Drug Market Size And Cagr
Figure 2020-2030 Mea Psoriasis Drug Market Size And Cagr
Figure 2020-2025 Global Psoriasis Drug Market Size And Growth Rate
Figure 2025-2030 Global Psoriasis Drug Market Size And Growth Rate
Research Methodology
- Market Estimated Methodology:
Bottom-up & top-down approach, supply & demand approach are the most important method which is used by HDIN Research to estimate the market size.
1）Top-down & Bottom-up Approach
Top-down approach uses a general market size figure and determines the percentage that the objective market represents.
Bottom-up approach size the objective market by collecting the sub-segment information.
2）Supply & Demand Approach
Supply approach is based on assessments of the size of each competitor supplying the objective market.
Demand approach combine end-user data within a market to estimate the objective market size. It is sometimes referred to as bottom-up approach.
- Forecasting Methodology
- Numerous factors impacting the market trend are considered for forecast model:
- New technology and application in the future;
- New project planned/under contraction;
- Global and regional underlying economic growth;
- Threatens of substitute products;
- Industry expert opinion;
- Policy and Society implication.
- Analysis Tools
1）PEST Analysis
PEST Analysis is a simple and widely used tool that helps our client analyze the Political, Economic, Socio-Cultural, and Technological changes in their business environment.
- Benefits of a PEST analysis:
- It helps you to spot business opportunities, and it gives you advanced warning of significant threats.
- It reveals the direction of change within your business environment. This helps you shape what you’re doing, so that you work with change, rather than against it.
- It helps you avoid starting projects that are likely to fail, for reasons beyond your control.
- It can help you break free of unconscious assumptions when you enter a new country, region, or market; because it helps you develop an objective view of this new environment.
2）Porter’s Five Force Model Analysis
The Porter’s Five Force Model is a tool that can be used to analyze the opportunities and overall competitive advantage. The five forces that can assist in determining the competitive intensity and potential attractiveness within a specific area.
- Threat of New Entrants: Profitable industries that yield high returns will attract new firms.
- Threat of Substitutes: A substitute product uses a different technology to try to solve the same economic need.
- Bargaining Power of Customers: the ability of customers to put the firm under pressure, which also affects the customer's sensitivity to price changes.
- Bargaining Power of Suppliers: Suppliers of raw materials, components, labor, and services (such as expertise) to the firm can be a source of power over the firm when there are few substitutes.
- Competitive Rivalry: For most industries the intensity of competitive rivalry is the major determinant of the competitiveness of the industry.
3）Value Chain Analysis
Value chain analysis is a tool to identify activities, within and around the firm and relating these activities to an assessment of competitive strength. Value chain can be analyzed by primary activities and supportive activities. Primary activities include: inbound logistics, operations, outbound logistics, marketing & sales, service. Support activities include: technology development, human resource management, management, finance, legal, planning.
4）SWOT Analysis
SWOT analysis is a tool used to evaluate a company's competitive position by identifying its strengths, weaknesses, opportunities and threats. The strengths and weakness is the inner factor; the opportunities and threats are the external factor. By analyzing the inner and external factors, the analysis can provide the detail information of the position of a player and the characteristics of the industry.
- Strengths describe what the player excels at and separates it from the competition
- Weaknesses stop the player from performing at its optimum level.
- Opportunities refer to favorable external factors that the player can use to give it a competitive advantage.
- Threats refer to factors that have the potential to harm the player.
- Data Sources
| Primary Sources | Secondary Sources |
|---|---|
| Face to face/Phone Interviews with market participants, such as: Manufactures; Distributors; End-users; Experts. Online Survey |
Government/International Organization Data: Annual Report/Presentation/Fact Book Internet Source Information Industry Association Data Free/Purchased Database Market Research Report Book/Journal/News |